Hypolipidemic agents
Hypolipidemic agents has been studied in 15 papers since 2013: 9 observational studies in people, 6 reviews; 7 in the past year. The newest paper, Jun 24, 2026: “Sex differences in the secondary and primary prevention of cardiovascular diseases among 75-year-olds in Southwest Finland: a population-based study”.
See all 15 papers on hypolipidemic agents
At a glance
The findings reach people, from one lab or study. 3 independent labs in 3 countries.
“men were more likely than women to use lipid-lowering (82% vs. 70%) (OR 1.95, 95% CI 1.08-3.49)”
None of its findings points the other way.
- 3 independent labs in 3 countries
- Funders: National Institute on Aging and 3 more
- Humans9
What did studies of hypolipidemic agents find?
2Studies of hypolipidemic agents measured 2 outcomes: Braak stage and PCSK9.
Braak stage
no changein humans1
1 study
Braak stage
no changein humans1
Hypolipidemic agents were not clearly linked with Braak stage in humans.
“LLR had no significant effect on Braak staging scores, hippocampal atrophy, and total CSF Tau level”
Humans
The journal of prevention of Alzheimer's disease
PCSK9
upin humans1
1 study
PCSK9
upin humans1
Hypolipidemic agents increase PCSK9 in humans (WMD 23.25 ng/mL, 95% CI 17.00–29.50, p < 0.01).
“Results indicate a significant increase in plasma PCSK9 levels following treatment with conventional lipid-lowering drugs (weighted mean difference: 23.25 ng/mL; 95% confidence interval: 17.00, 29.50; p < 0.01”
Reviewat least 2 weeksn = 1,313
Diabetes, obesity & metabolism
What is hypolipidemic agents linked with?
3Studies link hypolipidemic agents with 3 measures: male sex, mortality and cardiovascular disease.
Male sex
upin humans1OR 1.95
1 study
Male sex
upin humans1OR 1.95
Male sex is associated with hypolipidemic agents in humans (secondary prevention of CVD) (82% vs. 70%, OR 1.95, 95% CI 1.08-3.49).
“men were more likely than women to use lipid-lowering (82% vs. 70%) (OR 1.95, 95% CI 1.08-3.49)”
Humanssecondary prevention of CVD
BMC primary care
Mortality
downin humans1HR 0.822
1 study
Mortality
downin humans1HR 0.822
Hypolipidemic agents are linked with a lower risk of mortality in humans (dementia (CDR-SOB >=3)) (HR: 0.822 (0.746, 0.906)).
“and an increased rate of survival [HR: 0.822 (0.746, 0.906). P = 0.001].”
Humansdementia (CDR-SOB >=3)
The journal of prevention of Alzheimer's disease
Cardiovascular disease
downin humans1
1 study
Cardiovascular disease
downin humans1
Hypolipidemic agents lower the risk of cardiovascular disease in humans.
“Although these pharmacological agents seem to reduce the incidence of cardiovascular events, they do not prolong survival.”
Review
Hypolipidemic drugs in elderly subjects: Indications and limits
Nutrition, metabolism, and cardiovascular diseases : NMCD